S. Tsurumi

PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma

W. Takahashi, K. Sasaki, Kinuko Mitani, 2020, Leukemia & lymphoma.

N‐ras and p53 gene mutations in Japanese patients with myeloproliferative disorders

S. Ogawa, K. Mitani, H. Hirai, 2002, American journal of hematology.

Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group

H. Nakasone, K. Sakamoto, Y. Kanda, 2014, Journal of Thrombosis and Thrombolysis.

Successful HLA-identical Unrelated Allogeneic Bone Marrow Transplantation with a very Low Dose of Stem Cells for a Patient with Chronic Myeloid Leukemia in Blast Crisis

K. Mitani, K. Maki, Yuichi Nakamura, 2002, Leukemia & lymphoma.

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia wit

K. Saito, W. Takahashi, Y. Nakamura, 2000, International journal of hematology.

[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].

K. Mitani, W. Takahashi, K. Sasaki, 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology.